Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456149 | 0.81 | HDAC6 (0.38) | HDAC6HDAC1HDAC2DPP4CA1 | |
| SCHEMBL20033588 | 0.81 | HDAC6 (0.38) | HDAC6HDAC1HDAC2DPP4CA1 | |
| SCHEMBL15597130 | 0.80 | CYP2D6 (0.33) | HDAC6HDAC1HDAC2CYP2D6DPP4 | |
| SCHEMBL8280474 | 0.80 | DPP4 (0.35) | HDAC6HDAC1HDAC2DPP4CA1 | |
| SCHEMBL23134818 | 0.79 | MAPK1 (0.35) | HDAC6HDAC1HDAC2CYP2D6CA1 | |
| SCHEMBL20215933 | 0.79 | MAPK1 (0.35) | HDAC6HDAC1HDAC2CYP2D6CA1 | |
| SCHEMBL24573971 | 0.78 | HDAC6 (0.36) | HDAC6HDAC1HDAC2DPP4CA1 | |
| SCHEMBL14000449 | 0.78 | HDAC6 (0.36) | HDAC6HDAC1HDAC2DPP4CA1 | |
| SCHEMBL13490197 | 0.77 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CYP2D6CA1 | |
| SCHEMBL1447140 | 0.77 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CYP2D6CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | HDAC6 1007/4885HDAC1 892/4885HDAC2 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.